EUVIMEDOntdek EUVIMED
Crossref

The Effect of Empagliflozin Treatment on Epicardial Adipose Tissue and Cardiac Function in Patients With Type 2 Diabetes Mellitus

Yemlihan Ceylan, Elif Eker

Echocardiography · 2026-04 · 43 (4)

DOI: 10.1111/echo.70431 ↗

At a glance

Journal article in Echocardiography, published online on 2026-03-27. Written by Yemlihan Ceylan and 1 co-authors. Institution: Department of Cardiology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Türkiye. Major MEDLINE topics: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Epicardial Adipose Tissue, Glucosides. 29 references.

SamenvattingSubjectsBibliografische gegevensCiteRelated studies

Abstract (original language)

Background

This study evaluated the association of empagliflozin treatment with epicardial adipose tissue (EAT) thickness and cardiac function in patients with type 2 diabetes mellitus (T2DM) without established cardiovascular disease.

Methods

In this prospective single‐arm study, 75 adults with T2DM on stable oral antidiabetic therapy received empagliflozin 10 mg once daily for 6 months. Patients with known cardiovascular disease, heart failure, or renal dysfunction were excluded. Transthoracic echocardiography was performed at baseline and follow‐up to quantify EAT thickness and cardiac function parameters. Laboratory assessments included glycaemic indices, lipid profile, and inflammatory biomarkers. Changes (Δ) in EAT were correlated with changes in metabolic, inflammatory, and echocardiographic parameters.

Results

The cohort (mean age 58.5 ± 8.3 years; 44% male) exhibited a significant reduction in EAT thickness (from 0.77 ± 0.07 cm to 0.69 ± 0.06 cm; p < 0.001). Significant improvements were observed in fasting glucose (182 ± 60.2 to 132 ± 16.2 mg/dL; p < 0.001), HbA1c (9.17% ± 1.24% to 8.36% ± 1.01%; p < 0.001), LDL‐C (112 ± 28.9 to 106 ± 26.4 mg/dL; p < 0.001), HDL‐C (46.5 ± 10.5 to 47.5 ± 9.6 mg/dL; p < 0.001), CRP (3.95 ± 2.36 to 3.32 ± 0.71 mg/L; p = 0.005), and neutrophil‐to‐lymphocyte ratio (1.82 ± 0.61 to 1.66 ± 0.58; p = 0.016). Diastolic indices improved, including E/e′ (6.88 ± 2.03 to 6.64 ± 1.49; p = 0.011), isovolumic relaxation time (96.7 ± 10.7 to 93.6 ± 10.5 ms; p < 0.001), and deceleration time (214 ± 32.2 to 210 ± 29.6 ms; p < 0.001), whereas left ventricular ejection fraction remained stable (62.3% ± 1.47% vs. 62.5% ± 0.99%; p = 0.653). Among cardiovascular risk factors, only smoking was associated with higher baseline EAT thickness. ΔEAT did not correlate significantly with changes in HbA1c, BMI, CRP, NLR, LDL‐C, HDL‐C, or diastolic parameters, but showed a moderate inverse correlation with baseline EAT ( r = −0.51; p < 0.001).

Conclusion

Empagliflozin therapy was associated with significant EAT thinning and favorable within‐subject changes in selected diastolic indices and cardiometabolic markers in T2DM patients without established cardiovascular disease. The magnitude of EAT reduction was not significantly correlated with changes in conventional metabolic or inflammatory parameters; however, given the single‐arm design and absence of a control group, causal and mechanistic inferences cannot be made, and these findings should be considered hypothesis‐generating. Future controlled studies are warranted to confirm these observations and clarify underlying mechanisms.

Subjects

MeSH terms (MEDLINE)

Benzhydryl CompoundsDiabetes Mellitus, Type 2Epicardial Adipose TissueGlucosidesEchocardiographySodium-Glucose Transporter 2 InhibitorsHumansMaleMiddle AgedFemaleProspective StudiesTreatment Outcome

Author keywords

SGLT‐2 inhibitorsType 2 diabetes mellituscardiovascular riskdiastolic functionempagliflozinepicardial adipose tissue

Substances

Benzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Authors and institutions

  • Department of Cardiology, Faculty of Medicine, Van Yuzuncu Yil University, Van, Türkiye.
  • Department of Internal Medical Sciences, Faculty of Medicine, Osmangazi University, Eskişehir, Türkiye.

Cite

APA

Ceylan, Y., & Eker, E. (2026). The Effect of Empagliflozin Treatment on Epicardial Adipose Tissue and Cardiac Function in Patients With Type 2 Diabetes Mellitus. Echocardiography, 43(4). https://doi.org/10.1111/echo.70431

Vancouver

Ceylan Y, Eker E. The Effect of Empagliflozin Treatment on Epicardial Adipose Tissue and Cardiac Function in Patients With Type 2 Diabetes Mellitus. Echocardiography. 2026;43(4). doi:10.1111/echo.70431

BibTeX
@article{Ceylan2026,
  author = {Ceylan, Yemlihan and Eker, Elif},
  title = {The Effect of Empagliflozin Treatment on Epicardial Adipose Tissue and Cardiac Function in Patients With Type 2 Diabetes Mellitus},
  journal = {Echocardiography},
  year = {2026},
  volume = {43},
  number = {4},
  doi = {10.1111/echo.70431}
}
Start for free →